Onesource shares fall up to 7% on semaglutide supply delay, guidance cut from key client

Shares of OneSource Specialty Pharma declined 7.4% to hit an intraday low of ₹1,506.1 apiece on Friday. The stock has since, recovered from the lows of the day.

Shares of OneSource Specialty Pharma declined 7.4% to hit an intraday low of ₹1,506.1 apiece on Friday. The stock has since, recovered from the lows of the day.

Muthoot Microfin’s Collection efficiency improved to 97.97% in Q1FY27 from 93% a year ago and 96.43% in the March quarter. The company’s X-Bucket collection efficiency stood at 99.89%.

Krishna Sanghavi, Chief Investment Officer – Equities at Mahindra Manulife Investment Management, favours private banks, manufacturing, capital goods and defence, citing policy support, corporate investment and India’s shift towards bottom-up growth. Sanghavi added that upstream oil and gas companies with…

Revenue from operations rose 6% year-on-year to ₹521 crore, compared with ₹491 crore in the year-ago quarter.

Swarup Mohanty, Vice Chairman & CEO of Mirae Asset Mutual Fund and Pranav Haldea, MD of Prime Database Group explain why mutual funds are becoming more selective, what is driving IPO participation, and how a record pipeline of ₹5 lakh…

The transaction will combine complementary capabilities in defence systems and energetic materials in both companies, enable operational efficiencies and enhanced R&D, bring about broader participation in defence and space-related programmes and support next-generation defence and space programs.

Trading activity remained elevated, with around 4 crore shares changing hands by afternoon, compared with the 20-day average of 22 lakh shares. About 13% of the traded quantity had been marked for delivery.

This 49% upmove that Oracle Financial Services has seen this year is the second-best performance by the stock in a calendar year since 2012. Shares were up 203% back in 2024.

Moshe Katri, Managing Director-FinTech & Tech-Enabled Services Investment Banking at Wedbush Securities discusses why TCS’ April-June quarter of 2026 (Q1FY27) was better than feared, why concerns over Microsoft, Amazon and OpenAI are overblown, and why artificial intelligence (AI) could follow…

According to JPMorgan, Lenskart’s customer-centric approach, backed by investments in technology and data analytics, has created durable competitive advantages that justify its premium valuation.